Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.44 USD
Change Today -0.0108 / -2.40%
Volume 113.4K
IMUC On Other Exchanges
As of 8:04 PM 10/9/15 All times are local (Market data is delayed by at least 15 minutes).

immunocellular therapeutics (IMUC) Snapshot

Previous Close
Day High
Day Low
52 Week High
12/3/14 - $1.03
52 Week Low
08/24/15 - $0.35
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

immunocellular therapeutics (IMUC) Related Bloomberg News

View More Bloomberg News

immunocellular therapeutics (IMUC) Related Businessweek News

No Related Businessweek News Found

immunocellular therapeutics (IMUC) Details

ImmunoCellular Therapeutics, Ltd., a clinical-stage biotechnology company, develops immune-based therapies for the treatment of brain and ovarian cancers. Its lead product candidate includes ICT-107, a dendritic cell (DC) vaccine that completed Phase II testing trials for the treatment of glioblastoma multiforme (GBM). The company also develops other therapeutic DC vaccines, such as ICT-121 to treat recurrent GBM and other solid tumor cancers; and ICT-140 for ovarian cancer. In addition, it has a portfolio of other potential therapeutic immunotherapies to treat cancer. The company was formerly known as Optical Molecular Imaging, Inc. and changed its name to ImmunoCellular Therapeutics, Ltd. in November 2006. ImmunoCellular Therapeutics, Ltd. is based in Calabasas, California.

5 Employees
Last Reported Date: 03/10/15

immunocellular therapeutics (IMUC) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $533.1K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $207.1K
Senior Vice President of Strategic Resources
Total Annual Compensation: $400.3K
Founder, Consultant and Director
Total Annual Compensation: $161.4K
Compensation as of Fiscal Year 2014.

immunocellular therapeutics (IMUC) Key Developments

Immunocellular Therapeutics, Ltd. Announces the Resignation of Dr. John Yu as Chief Scientific Office

ImmunoCellular Therapeutics, Ltd. announced the resignation of Dr. John Yu as Chief Scientific Officer, effective October 1, 2015. Dr. Yu will remain a member of the board of directors of the company, but will no longer serve as chairman. Dr. Yu will continue to provide services to the company pursuant to a consulting agreement, effective October 1, 2015. Pursuant to the Agreement, Dr. Yu will provide consulting services to the company, including supporting the execution of the phase 3 clinical trial of ICT-107 and assisting with the evaluation and acquisition of outside technology.

ImmunoCellular Therapeutics, Ltd. Proposes Amendment to Certificate of Incorporation

ImmunoCellular Therapeutics, Ltd. announced that at the EGM to be held on November 16, 2015, it will propose amendment to the company's amended and restated certificate of incorporation to increase the authorized number of shares of common stock from 149,000,000 to 249,000,000.

ImmunoCellular Therapeutics, Ltd. Announces Executive Appointments

ImmunoCellular Therapeutics, Ltd. announced that its Board of Directors has appointed Mark A. Schlossberg and Gregg A. Lapointe as Board members. Mr. Schlossberg has been appointed to the Audit and Nominating & Governance Committees of the Board, and Mr. Lapointe has been appointed to the Compensation Committee of the Board. Mr. Schlossberg currently serves as Senior Vice President, General Counsel and Corporate Secretary of Impax Laboratories Inc., where he is part of the senior management team responsible for the strategic direction and financial condition of the company. He leads the legal team and previously had responsibility for the healthcare compliance team. Prior to Impax, he served as Vice President, Associate General Counsel of Amgen Inc., where he led the legal department, and was responsible for corporate governance, securities law, licensing, mergers and acquisitions, global operations, and sales and marketing compliance. Mr. Lapointe is currently the Chief Executive Officer of Cerium Pharmaceuticals Inc. He previously served as Chief Operating Officer and then as Chief Executive Officer of Sigma-Tau Pharmaceuticals Inc. and the U.S. wholly-owned subsidiary of Sigma-Tau Finanziaria S.p.A.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IMUC:US $0.44 USD -0.0108

IMUC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IMUC.
View Industry Companies

Industry Analysis


Industry Average

Valuation IMUC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 1.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMMUNOCELLULAR THERAPEUTICS, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at